Craig-Hallum Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $35

Craig-Hallum analyst Chase Knickerbocker maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $30 to $35.